Nimotuzumab Concurrent with Gemcitabine as First-Line Treatment of Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Figure 3

The Kaplan-Meier curves for overall survival in treatment patients with 8 or more doses of nimotuzumab and according to disease status at inclusion. SD: standard deviation; CI: confidence interval.